WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
========================================

-   Droperidol is a highly effective sedative and anti-emetic agent.

-   It has been removed or highly restricted because of concerns about QT prolongation and torsades de pointes.

-   Outside of spontaneous reporting there is limited published evidence that droperidol causes QT prolongation.

WHAT THIS STUDY ADDS
====================

-   QT prolongation was associated with high dose droperidol for sedation in acute agitated patients.

-   In patients with QT prolongation, this could be attributed to another drug or pre-existing cardiac disease in all cases.

Introduction
============

Droperidol is a butyrophenone, antipsychotic medication that has been used extensively for decades to sedate patients with acute behavioural disturbance \[[@b1]\]. There have been concerns about the safety of droperidol because of its association with torsades des pointes (TdP) and QT prolongation \[[@b2]\]. Despite little evidence to support these claims \[[@b3]\], a black box warning was imposed by the United States Food and Drug Administration (FDA) in 2001 \[[@b3], [@b4]\] and other international drug regulatory bodies have removed it or restricted its use. This has led to a rapid decrease in its use and lack of availability \[[@b5]\].

Acute behavioural disturbance is common in the emergency department and often manifests as violence and aggression. Such behaviours put both staff and patients at risk of harm and can result in damage to property and injury \[[@b6]\]. Patients who cannot be settled by verbal de-escalation methods or oral sedation require mechanical restraint and parenteral sedation \[[@b7]\]. There is increasing evidence that droperidol is an effective drug for rapid sedation and it appears to be safer than benzodiazepines, because the latter cause over-sedation and require more additional sedation \[[@b8]--[@b11]\]. The increasing evidence for the benefit of droperidol \[[@b8]--[@b11]\] and the long safety record prior to the black box warning \[[@b12]\] means that there needs to be a reassessment of its safety so that a potentially beneficial drug is not restricted without good reason.

Although a number of studies have reported the association between droperidol and QT prolongation \[[@b13]\], they have not used standardized approaches to measuring the QT interval or have used Bazett\'s formula for heart rate (HR) correction, which over-corrects with heart rates greater than 70 beats min^--1^ \[[@b14]\]. There is limited information on electrocardiogram (ECG) changes following the administration of high dose droperidol for sedating agitated patients. Such studies have used a limited number of 12-lead ECGs \[[@b8], [@b9], [@b15]\]. A better understanding of the ECG changes following large doses of droperidol is required to provide a better assessment of the risk of QT prolongation and TdP in this setting.

The aim of this study was to investigate the cardiac effects of droperidol by accurately measuring the QT interval after the administration of droperidol using high resolution continuous 12-lead Holter recordings and assessing the risk of TdP using the QT nomogram \[[@b16]\].

Methods
=======

This was a prospective study of patients given droperidol, which used high resolution Holter recordings to investigate the effect of high dose droperidol on the ECG and in particular, its effect on the QT interval. Patients were recruited as part of the DORM II study. DORM II is an observational study of patients with aggression or agitation presenting to the emergency department requiring parenteral sedation and physical restraint. Ethics approval was obtained from the local Human Research Ethics Committee. Due to the lack of decision making capacity in these patients and a duty of care to sedate them, patient consent was waived by the ethics committee.

Patients were included in this study between September 2009 and June 2011 from one hospital emergency department site involved in the DORM II study where there was access to Holter recordings. This was an urban emergency department with 30 000 annual presentations and approximately 5.5 presentations per 1000 with violence and/or agitation requiring parenteral sedation.

The DORM II study recruits adult patients (\>16 years of age) presenting to the emergency department with violence and/or agitation who do not settle with verbal de-escalation or the administration of oral medication. A standardized intramuscular sedation protocol is followed for all patients, including routine observations (heart rate \[HR\], blood pressure \[BP\], respiratory rate \[RR\] and pulse oximetry) \[[@b6], [@b8]\] and the sedation assessment tool (SAT) to monitor agitation and sedation \[[@b17]\]. All patients are initially administered 10 mg intramuscular droperidol and if they do not settle within 15 min they are given a second dose of 10 mg. If patients still do not settle 30 min after their initial assessment, further sedation with droperidol is determined by the clinical toxicologist.

A purpose-designed chart was completed for all patients in the DORM II study, including observations, treatments and adverse effects. Once the patient was settled they had an ECG done and in this study were assessed by the nursing staff for suitability for a Holter recording. Patients were recruited if they were settled enough for a Holter recorder and its 12 leads to be attached, and the patient was able to tolerate this for at least 2 h. The duration of recording was for as long as the patient tolerated the Holter leads, until the patient was discharged or transferred, or 24 h had passed (maximum length of the digital Holter recording). Patients were excluded if they were not in sinus rhythm. The following data were included for the study: age, gender, drugs taken prior to droperidol and the dose and timing of droperidol.

For each admission 12-lead ECGs were extracted from the digital Holter recordings as follows. The H12+24 Hour Digital Holter Recorder (Mortara, Inc.) records a continuous 12-lead ECG onto a 24 h compact flash card. Continuous 12-lead Holter recording data were then acquired via a card reader and downloaded to a desktop computer using proprietary software (H-Scribe; Mortara, Inc.). The software allows the continuous 12-lead recordings to be stored and reviewed. The trend setting was used to determine if any arrhythmias had occurred and then high resolution digital 12-lead ECGs were extracted from the Holter recordings using H-Scribe. A 10 s 12-lead ECG was extracted every hour from the recording. The 12-lead ECGs were imported into E-scribe (Mortara, Inc.) to measure the QT interval. The E-Scribe software includes an algorithm to measure automatically the QT interval which includes averaging over multiple beats in each lead. It then displays the computer measured QT in a magnified view with the six chest and six limb leads separately overlayed, an overlay or butterfly view. On screen callipers are provided to adjust manually the QT interval if required. The measurement of the QT interval was reviewed by a clinical pharmacologist/toxicologist with expertise in the measurement and assessment of the QT. The QT interval was recorded for each ECG as well as the HR. Each QT interval measurement was plotted against the HR on the QT nomogram \[[@b16], [@b18]\]. Any QT--HR pair that was above the line on the QT nomogram was defined as abnormal. QT~c~F (Fridericia\'s HR correction of the QT interval) was also calculated and a cut-off of 500 ms was defined as abnormal.

The primary outcome for this study was the proportion of patients who had any QT--HR pairs above the 'at risk' line on the QT nomogram \[[@b16]\]. Secondary outcomes included QT~c~F \> 500 ms and arrhythmias occurring after the administration of droperidol. Medians, ranges and interquartile ranges (IQR) are reported for continuous variables. Graphical analyses were done in GraphPad Prism version 5.03 for Windows, GraphPad Software, San Diego, California, USA, <http://www.graphpad.com>.

Results
=======

There were forty-six patient admissions, 33 males and 13 females with a median age of 34 years (IQR 25 to 41 years, range 17 to 85 years) included in the study from which 3 to 23 12-lead ECGs were obtained for each admission. Three patients were excluded, two with chronic atrial fibrillation and one with left bundle branch block. Two patients had a second recording on a separate admission. Twenty-nine patients received 10 mg droperidol, 11 received 20 mg, three received 30 mg and three received 40 mg. The Holter recording was commenced a median of 60 min (IQR 38 to 111 min, range 16 to 307 min) after the first administration of droperidol. The median duration of the recordings was 6 h (range 2 to 24 h). A total of 316 QT--HR pairs were included and 284 QT--HR pairs were below the 'at risk line on the QT nomogram (Figure [1](#fig01){ref-type="fig"}). Thirty-two QT--HR pairs in four patients were above the 'at risk' line (Figure [2](#fig02){ref-type="fig"}). The QT~c~F was greater than 500 ms in three of the four patients (three male patients, Table [1](#tbl1){ref-type="table"}). Figure [3](#fig03){ref-type="fig"} shows the time course of QT~c~F after the administration of droperidol. None of six patients who received 30 or 40 mg droperidol had an abnormal QT. No patient had an arrhythmia and TdP did not occur in the four patients with prolonged QT intervals.

![Plot of the QT interval *vs*. heart rate for the 42 patient admissions where the QT was normal. , normal QT; , abnormal QT](bcp0077-0880-f1){#fig01}

![Plot of the QT interval *vs*. heart rate for the four patients with an abnormal QT interval (see Table [1](#tbl1){ref-type="table"}). , 52M patients; , 41M patient; , 25M patient; , 17F patient](bcp0077-0880-f2){#fig02}

###### 

Details of the four patients with QT prolongation

  Age/gender   Dose (mg)   Reason for presentation                       History                                                                     Time to QT prolongation (min)   Maximum QT interval (ms)   Heart rate (beats min^−1^)
  ------------ ----------- --------------------------------------------- --------------------------------------------------------------------------- ------------------------------- -------------------------- ----------------------------
  **41 M**     10          Hallucinations due to amphetamines            Poly-substance abuse. Urine drug screen positive for amphetamines and THC   210                             522                        53
  **25 M**     20          Amphetamine toxicity and agitation            Taking methadone confirmed on urine drug screen.                            50 (start of recording)         512                        59
  **52 M**     10          Attempted suicide with liquid petroleum gas   Poly-substance abuse. Urine drug screen positive for THC, amphetamines      260                             534                        39
  **17 F**     10          Lamotrigine overdose                          Post-natal depression                                                       110 (start of recording)        505                        40

THC, tetrahydrocannibinol.

![Plot of the QT~c~F *vs*. time for the four patients with an abnormal QT. , 41M patient; , 52M patient; , 25M patient; , 17F patient; , repeat droperidol dose](bcp0077-0880-f3){#fig03}

Details of the four patients with a prolonged QT are included in Table [1](#tbl1){ref-type="table"}. The first patient presented to the emergency department with hallucinations after using amphetamines. He was a regular illicit intravenous drug user and a carrier of hepatitis C. His urine drug screen was positive for amphetamines and tetrahydrocannibinol. The Holter monitor was placed 1 h after droperidol 10 mg and the QT was normal until it became prolonged 11 h after droperidol (Figure [3](#fig03){ref-type="fig"}, blue line). The second patient had been on methadone for 6 months and an ECG obtained prior to methadone commencing was normal. He was given 20 mg droperidol and the Holter placed 50 min after this. The QT interval was prolonged from the start until the end of the Holter recording 7.5 h after droperidol (Figure [3](#fig03){ref-type="fig"}, red line). The third patient was a homeless intravenous drug user who attempted suicide using liquid petroleum gas inhalation. The Holter was placed 2.25 h after droperidol was administered. QT prolongation appeared 4.33 h after droperidol was administered and remained prolonged on discharge the next morning. However, the QT~c~F remained less than 500 ms except for on ECG recording 13.66 h post-droperidol (Figure [3](#fig03){ref-type="fig"}, green line). The patient also remained bradycardic on discharge and never had a HR greater than 60 beats min^--1^. Despite repeated attempts the patient could not be contacted for cardiology follow-up. The fourth patient was female with post-natal depression who took an overdose of 2800 mg lamotrigine. The Holter was placed 1 h and 50 min after droperidol was administered. The QT interval was prolonged from the start of the Holter recording and resolved over several hours. She was also bradycardic and had a HR less than 60 beats min^--1^ for the duration. Her QT~c~F remained less than 500 ms for the duration.

Discussion
==========

QT prolongation occurred in four patients after high dose droperidol administration and in these patients with an abnormal QT, there was little evidence to support droperidol being the cause. In at least one of the four patients with an abnormal QT, another drug was more likely to be the cause (methadone treatment). In addition, there was no dose dependence with droperidol and the QT prolongation, because QT prolongation occurred in three patients given 10 mg and one given 20 mg and there was no QT prolongation in patients given larger doses. The study used accurate measurement of the QT interval and a previously evaluated approach to determining abnormal QT intervals associated with TdP \[[@b18]\]. By employing continuous recording over many hours we were able to determine when the QT prolongation occurred in relation to the droperidol dose using QT~c~F (Figure [3](#fig03){ref-type="fig"}). This intensive sampling in the first few hours after droperidol administration also meant we did not rely on one or two ECGs, or single lead ECG recordings. Importantly, no arrhythmias occurred including those who had a prolonged QT interval.

In the four patients with abnormal QT intervals, the QT prolongation could reasonably be attributed to other drugs or a pre-existing condition (e.g. undiagnosed cardiac condition). Two males with an abnormal QT were taking therapeutic drugs known to prolong the QT interval (methadone) or taking illicit drugs (e.g. amphetamines) (Table [1](#tbl1){ref-type="table"}). The female patient presented with a large lamotrigine overdose and had a prolonged QT on the QT nomogram from the time the Holter was commenced. Lamotrigine has been shown to inhibit the human cardiac delayed rectifier potassium current *in vitro* and may be associated with QT prolongation \[[@b19]\]. This patient had a slow heart rate and the QT~c~F was never greater than 500 ms (Figure [3](#fig03){ref-type="fig"}). The other male patient with poly-substance abuse had unresolved QT prolongation and bradycardia on discharge and was lost to cardiology follow-up. Such factors as undiagnosed pre-existing cardiac disease or other drugs are substantial confounders in this patient cohort who presented to the ED with agitation and violence. However, it is not possible to exclude droperidol completely as a contributing factor in these four patients.

The change in QT~c~F over time, shown in Figure [3](#fig03){ref-type="fig"}, also provides some insight into whether the abnormal QT was due to droperidol. The patient on methadone (25-year-old male, Figure [3](#fig03){ref-type="fig"}) clearly had an abnormal QT~c~F for the duration of the Holter recording. However, for the other two male patients, the QT~c~F was only abnormal between 12 and 18 h after droperidol, not consistent with the expected pharmacokinetics of droperidol.

This study used accurate measurement of the QT interval \[[@b20]\] and a previously evaluated approach to determining abnormal QT intervals \[[@b16], [@b18]\]. Two early studies prior to the black box warning issued by the FDA suggested that QT prolongation occurred with high dose droperidol \[[@b13], [@b21]\]. However, in both studies there were problems with QT measurement and the heart rate correction of the QT interval, and both studies were done in patients under general anaesthesia. A more recent study of patients undergoing general anaesthesia found that similar numbers of patients had QT prolongation if they were given normal saline or droperidol \[[@b22]\]. The first of the two earlier studies by Guy *et al*. \[[@b21]\] provided no information on the method of measuring the QT and used the mean of the QT from different leads, which provides a biased estimate of the QT interval \[[@b23]\]. Lischke *et al*. used an automatic measurement from a standard ECG machine and also used the mean of the QT from different leads \[[@b13]\]. Both studies used Bazett\'s formula to correct for HR which is known to over-correct in patients with HRs faster than 70 beats min^--1^ \[[@b24], [@b25]\]. This may account for the unusual finding by Lischke *et al*. that the mean maximal QT prolongation occurred within 1 min of drug administration, at the same time as a significant increase in HR. In addition, the rapid rise and fall of the QT~c~ in the study by Lischke *et al*. is not consistent with the known slow adaptation of the QT interval to sudden or rapid changes in HR due to QT hysteresis \[[@b26]\]. A more recent study by Charbit *et al*. suggested there was a significant change in the QT~c~B (Bazett\'s) following droperidol (compared with ondansetron). However, they showed rather erratic changes in the QT~c~B commencing minutes after the administration of droperidol, which did not account for inter-individual variation in HR correction or QT hysteresis, making these results difficult to interpret \[[@b27]\].

In our study the QT nomogram was the major method used to determine if the QT was abnormal \[[@b18]\]. The QT nomogram provides a different approach to assessing whether a QT interval is abnormal because the QT is plotted against the HR avoiding the need for HR correction formulae. However, it is not possibly to plot easily the QT--HR pair *vs*. time to determine if the abnormal QT coincides with the dosing of droperidol. We therefore used QT~c~F to explore this relationship in the patients with an abnormal QT, despite QT~c~F being a population based HR correction formula which can be problematic for fast and slow HRs \[[@b16]\].

The use of automated measurement of the QT interval using standard ECG machines is known to be inaccurate \[[@b14], [@b28]\]. In this study we used an automated QT measurement in dedicated software for the measurement of QT which also allowed the use of on-screen magnification and callipers for manual checking of the QT measurement by a clinician experienced in reading ECGs \[[@b14]\]. This approach provided the most accurate method of QT measurement and the application of this in a clinical setting is unique to the study.

A limitation of this study was the variability of the commencement time of the continuous Holter recordings. This was determined by the time to sedation but in 75% of the patients the Holter was commenced within 2 h. The compliance of the patients was imperative and was difficult to predict. Another problem was that the study did not include patients where it was unsafe or not possible to put on the Holter recording device. However, this was rare and was unlikely to have biased the patient group included in the study.

The absence of baseline ECGs is also a limitation of the study but it is not possible and unsafe to attempt to record an ECG or Holter in violent and agitated patients. There is limited data on the underlying frequency of QT prolongation in this population of patients presenting with acute behavioural disturbance. Three previous studies of droperidol in this population found no significant difference between patients given another drug for sedation (midazolam or olanzapine) *vs.* patients given droperidol \[[@b8], [@b9], [@b15]\]. In the DORM study there was no difference in the number of patients with an abnormal QT with two of 31 given 10 mg droperidol, two of 29 given 10 mg midazolam and four of 29 given 5 mg midazolam and 5 mg droperidol \[[@b8]\]. In another study where droperidol was compared with olanzapine or control, in patients already receiving midazolam, the median QT~c~B (Bazett\'s) intervals in 211 patients having an ECG did not differ between groups and was between 440 ms and 450 ms. One patient given olanzapine and one patient in the control group (midazolam alone) had QT~c~B measurements of 500 ms and 512 ms respectively. These studies suggest that there is a larger proportion of patients in this population who have an abnormal QT~c~B, with a higher median of 440 to 450 ms \[[@b15]\] compared with normal populations of 410 to 420 ms \[[@b29]\] and a greater number of outliers \[[@b8], [@b15]\]. The number of patients in our study with an abnormal QT on the Holter is consistent with this. Studies in other populations have also found that QT prolongation is often present in a proportion of patients prior to the administration of droperidol. In a study comparing droperidol and ondansetron for postoperative nausea and vomiting, 21% of patients had a long QT~c~B pre-operatively before any drug was administered \[[@b30]\].

Although QT prolongation was observed with high dose droperidol in this study, there was little evidence to support droperidol being the cause and QT prolongation was more likely to be due to pre-existing conditions or other drugs. There was also no evidence of dose dependence in cases where QT prolongation occurred.
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